CIPRO
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Dec 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
CIPRO by Bayer is 12. Approved for plague, including pheumonic, septicemic plague and 25 more indications. First approved in 1990.
Drug data last refreshed 2h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CIPRO (ciprofloxacin) is a fluoroquinolone antibiotic administered by injection for treatment of serious bacterial infections including plague, respiratory tract infections, skin and joint infections, and gonorrhea. It works by inhibiting bacterial DNA gyrase, disrupting DNA replication in susceptible gram-negative and gram-positive organisms. The product addresses high-acuity infections requiring parenteral therapy.
LOE Approaching
Product approaching loss of exclusivity with low competitive pressure score (30/100), indicating limited commercial investment and team contraction likely ahead.
Mechanism of Action
12.1 Mechanism of Action Ciprofloxacin is a member of the fluoroquinolone class of antibacterial agents [see ]. 12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism.…
Worked on CIPRO at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.